Browsing "1. Journal Papers" by Author : 4740

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:
  • Sort by:
  • In order:
  • Results/Page
  • Authors/Record:

Showing results 46 to 96 of 96

This table browses all dspace content
Issue DateTitleJournal Title
2019Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 studyLANCET ONCOLOGY
2023Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter studyLUNG CANCER
2022Lazertinib: on the Way to Its Throne YONSEI MEDICAL JOURNAL
2022Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapyRADIOTHERAPY AND ONCOLOGY
2019Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing PLOS ONE
2022Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2020Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response BRITISH JOURNAL OF CANCER
2020Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck BRITISH JOURNAL OF CANCER
2019Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate PLOS ONE
2021Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents KIDNEY RESEARCH AND CLINICAL PRACTICE
2010Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial designCANCER CHEMOTHERAPY AND PHARMACOLOGY
2021Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patientsJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2021Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma SCIENTIFIC REPORTS
2019Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma SCIENTIFIC REPORTS
2016PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients SCIENTIFIC REPORTS
2020Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer SCIENTIFIC REPORTS
2023Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH TrialJOURNAL OF CLINICAL ONCOLOGY
2020Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinomaCANCER
2014Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxaneCANCER CHEMOTHERAPY AND PHARMACOLOGY
2022Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2023Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies CANCERS
2017Povidone-iodine for the management of oral mucositis during cancer therapy Oncology Reviews
2023Preclinical Study of a Biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLCCLINICAL CANCER RESEARCH
2022Predicting treatment outcomes using 18 F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2019Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitorsCancer Chemotherapy and Pharmacology
2022Primary Tumor Suppression and Systemic Immune Activation of Macrophages through the Sting Pathway in Metastatic Skin Tumor YONSEI MEDICAL JOURNAL
2009Prognosis of pN3 stage gastric cancer CANCER RESEARCH AND TREATMENT
2023Prognostic value of baseline and early treatment response of neutrophil-lymphocyte ratio, C-reactive protein, and lactate dehydrogenase in non-small cell lung cancer patients undergoing immunotherapy TRANSLATIONAL LUNG CANCER RESEARCH
2023Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing CANCER RESEARCH AND TREATMENT
2019Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer YONSEI MEDICAL JOURNAL
2021Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
2020Recurrent Sympathetic Ophthalmia with Annular Choroidal Detachment after Pembrolizumab Treatment: A Case ReportOCULAR IMMUNOLOGY AND INFLAMMATION
2020Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer CLINICAL CANCER RESEARCH
2022Role of postoperative radiotherapy in resected adenoid cystic carcinoma of the head and neck RADIATION ONCOLOGY
2022SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models CLINICAL & TRANSLATIONAL IMMUNOLOGY
2024SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer JOURNAL OF CLINICAL ONCOLOGY
2011Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles.ONCOLOGY
2019Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer EMBO MOLECULAR MEDICINE
2022The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges FRONTIERS IN ONCOLOGY
2020The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma JOURNAL OF THORACIC DISEASE
2022The importance of enhancer methylation for epigenetic regulation of tumorigenesis in squamous lung cancer EXPERIMENTAL AND MOLECULAR MEDICINE
2023The prognostic value of comprehensive geriatric assessment on the management of older patients with small cell lung cancer KOREAN JOURNAL OF INTERNAL MEDICINE
2022The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report ESMO OPEN
2022Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22 TRANSLATIONAL LUNG CANCER RESEARCH
2022Treatment outcomes and radiotherapy deintensification strategies in human papillomavirus-associated tonsil cancer RADIATION ONCOLOGY
2009Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea CANCER RESEARCH AND TREATMENT
2021Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort StudyCLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
2023Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea DRUGS-REAL WORLD OUTCOMES
2023Usefulness of bronchial washing fluid for detection of EGFR mutations in non-small cell lung cancer LUNG CANCER
2019YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung CancerCLINICAL CANCER RESEARCH
2022YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment FRONTIERS IN CHEMISTRY
12

Browse

Links